Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

 Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

Shots:

  • The approval is based on P-II KEYNOTE-629 study assessing Keytruda (200mg, IV, q3w) in 105 patients with recurrent or metastatic cSCC that is not curable by surgery or radiation
  •  Results: ORR (34%); CR (4%) PR (31%); 69% had ongoing responses of six months or longer, @ follow-up time of 9.5mos. DOR has not reached
  • Keytruda is an anti-PD-1 therapy, acts by increasing the ability of the body’s immune system to help detect and fight tumor cells. The approval marks the first indication for Keytruda in cSCC

Click here to read full press release/ article | Ref: Businesswire | Image: NJ.com

Related News: Merck’s Keytruda Receives the NMPA’s Approval as a 2L Treatment for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post